Allergic rhinitis (AR) is a chronic inflammatory reaction by immunoglobulin E (IgE) mediators after individual contact with allergens. It affects 10–40% of the world’s population and reduces the quality of life. Long-term symptoms of rhinitis can cause inflammation to spread and trigger asthma, which can harm human health. Herein, we develop a Smart PeptIde defeNse (SPIN) web technique, which in situ constructs a peptide web, trapping IgE against AR. Two candidate SPINs, SPIN-1 and SPIN-2, are designed with different IgE-binding sequences. The SPIN-1 or SPIN-2 is able to bind to IgE and transform from nanoparticles into entangled nanofibers. In turn, the web of SPIN-1 or SPIN-2 acts as a long-term trap of IgE to prevent the IgE from binding to mast cells. SPIN-1 or SPIN-2 (10 mg/kg) is able to treat AR model Balb/c mice with high efficiency and reduced symptoms of rhinitis and inflammatory factors, even better than a first-line clinical drug, cetirizine (10 mg/kg). For example, the amount of IL-4 released in the AR group (185.5 ± 6.8 pg/mL) is significantly reduced after the treatment with SPIN-1 (70.4 ± 14.1 pg/mL), SPIN-2 (86.0 ± 9.3 pg/mL), or cetirizine (112.8 ± 19.3 pg/mL). More importantly, compared with the cetirizine group (1 day), the SPIN-1 or SPIN-2 group shows long-term therapeutic effects (1 week). The SPIN web technique shows the great potential for blocking IgE binding to mast cells in vivo, attenuating AR or other allergic reactions.

中文翻译：

---

智能肽防御网络原位连接用于持续拦截 IgE 对抗过敏性鼻炎

过敏性鼻炎 (AR) 是个体接触过敏原后免疫球蛋白 E (IgE) 介质引起的慢性炎症反应。它影响了世界人口的 10-40%，并降低了生活质量。鼻炎的长期症状会导致炎症扩散并引发哮喘，从而损害人类健康。在此，我们开发了一个Smart P ept I de defe Nse (SPIN) 网络技术，它在原位构建肽网络，将 IgE 捕获到 AR。两个候选 SPIN，SPIN-1 和 SPIN-2，设计有不同的 IgE 结合序列。SPIN-1 或 SPIN-2 能够与 IgE 结合并从纳米颗粒转变为缠结的纳米纤维。反过来，SPIN-1 或 SPIN-2 的网充当 IgE 的长期陷阱，以防止 IgE 与肥大细胞结合。SPIN-1 或 SPIN-2 (10 mg/kg) 对 AR 模型 Balb/c 小鼠的治疗效率高，减轻鼻炎和炎症因子的症状，甚至优于临床一线药物西替利嗪 (10 mg/公斤）。例如，AR 组释放的 IL-4 量（185.5 ± 6.8 pg/mL）在用 SPIN-1（70.4 ± 14.1 pg/mL）、SPIN-2（86.0 ± 9.3 pg/mL）治疗后显着降低。 mL) 或西替利嗪 (112.8 ± 19.3 pg/mL)。更重要的是，与西替利嗪组（1天）相比，SPIN-1或SPIN-2组显示出长期治疗效果（1周）。SPIN 网络技术显示出在体内阻断 IgE 与肥大细胞结合、减弱 AR 或其他过敏反应的巨大潜力。